Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther September 1 2014 13 (9) 2139-2139;

Review

  • Review
    Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
    Clémence Feneyrolles, Aurélia Spenlinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé and Aziz Yasri
    Mol Cancer Ther September 1 2014 13 (9) 2141-2148; DOI:10.1158/1535-7163.MCT-13-1083

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Direct Inhibition of Choline Kinase by a Near-Infrared Fluorescent Carbocyanine
    Sean P. Arlauckas, Anatoliy V. Popov and Edward J. Delikatny
    Mol Cancer Ther September 1 2014 13 (9) 2149-2158; DOI:10.1158/1535-7163.MCT-14-0085

  • Small Molecule Therapeutics
    Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
    Anaïs Balbous, Brigitte Renoux, Ulrich Cortes, Serge Milin, Karline Guilloteau, Thibaut Legigan, Pierre Rivet, Odile Boissonnade, Sébastien Martin, Caroline Tripiana, Michel Wager, René Jean Bensadoun, Sébastien Papot and Lucie Karayan-Tapon
    Mol Cancer Ther September 1 2014 13 (9) 2159-2169; DOI:10.1158/1535-7163.MCT-13-1038

  • Small Molecule Therapeutics
    Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
    Jessica J. Huck, Mengkun Zhang, Jerome Mettetal, Arijit Chakravarty, Karthik Venkatakrishnan, Xiaofei Zhou, Rob Kleinfield, Marc L. Hyer, Karuppiah Kannan, Vaishali Shinde, Andy Dorner, Mark G. Manfredi, Wen Chyi Shyu and Jeffrey A. Ecsedy
    Mol Cancer Ther September 1 2014 13 (9) 2170-2183; DOI:10.1158/1535-7163.MCT-14-0027

  • Small Molecule Therapeutics
    Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
    Yi-Xiang Zhang, Ewa Sicinska, Jeffrey T. Czaplinski, Stephen P. Remillard, Samuel Moss, Yuchuan Wang, Christopher Brain, Alice Loo, Eric L. Snyder, George D. Demetri, Sunkyu Kim, Andrew L. Kung and Andrew J. Wagner
    Mol Cancer Ther September 1 2014 13 (9) 2184-2193; DOI:10.1158/1535-7163.MCT-14-0387

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein
    Dmitrij Hristodorov, Manal Amoury, Radoslav Mladenov, Judith Niesen, Katharina Arens, Nina Berges, Lea Hein, Stefano Di Fiore, Anh-Tuan Pham, Michael Huhn, Wijnand Helfrich, Rainer Fischer, Theo Thepen and Stefan Barth
    Mol Cancer Ther September 1 2014 13 (9) 2194-2202; DOI:10.1158/1535-7163.MCT-13-0781

Cancer Biology and Signal Transduction

  • Cancer Biology and Signal Transduction
    Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
    Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma and George R. Stark
    Mol Cancer Ther September 1 2014 13 (9) 2203-2214; DOI:10.1158/1535-7163.MCT-14-0013

Companion Diagnostics and Cancer Biomarkers

  • Companion Diagnostics and Cancer Biomarkers
    Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
    Naoki Mine, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff and Takumi Kawabe
    Mol Cancer Ther September 1 2014 13 (9) 2215-2225; DOI:10.1158/1535-7163.MCT-13-0808

  • Companion Diagnostics and Cancer Biomarkers
    Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
    Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joan Maurel, Nuria Rodríguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrada, Esther Díaz-López, Antonio Sánchez, Rosario Madero, Paloma Cejas and Jaime Feliu
    Mol Cancer Ther September 1 2014 13 (9) 2226-2237; DOI:10.1158/1535-7163.MCT-13-1109

  • Companion Diagnostics and Cancer Biomarkers
    Epidermal Growth Factor–like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer
    Torben Frøstrup Hansen, Boye Schnack Nielsen, Flemming Brandt Sørensen, Anders Johnsson and Anders Jakobsen
    Mol Cancer Ther September 1 2014 13 (9) 2238-2245; DOI:10.1158/1535-7163.MCT-14-0131

Corrections

  • Corrections
    Correction: Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
    Mol Cancer Ther September 1 2014 13 (9) 2246-2247; DOI:10.1158/1535-7163.MCT-14-0497

  • Corrections
    Correction: Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death
    Mol Cancer Ther September 1 2014 13 (9) 2248-2249; DOI:10.1158/1535-7163.MCT-14-0537

  • Corrections
    Correction: The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
    Mol Cancer Ther September 1 2014 13 (9) 2250-2250; DOI:10.1158/1535-7163.MCT-14-0586

Back to top
PreviousNext
Molecular Cancer Therapeutics: 13 (9)
September 2014
Volume 13, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein
  • Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
  • Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
  • Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer

Jump to

  • Highlights
  • Review
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Signal Transduction
  • Companion Diagnostics and Cancer Biomarkers
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement